Publicacións en colaboración con investigadores/as de David Geffen School of Medicine at UCLA (19)

2024

  1. Dispersal history of SARS-CoV-2 in Galicia, Spain

    Journal of Medical Virology, Vol. 96, Núm. 7

  2. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

  3. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76

2023

  1. Influence of Otolaryngological Subspecialties on Perception of Transoral Robotic Surgery: An International YO-IFOS Survey

    Journal of Personalized Medicine, Vol. 13, Núm. 12

  2. Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial

    JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788

  3. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10371, pp. 105-117

2021

  1. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 1, pp. 51-65

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet, Vol. 396, Núm. 10253, pp. 759-769

2019

  1. Effects of serelaxin in patients with acute heart failure

    New England Journal of Medicine, Vol. 381, Núm. 8, pp. 716-726

2017

  1. Diffusion tensor imaging as a prognostic biomarker for motor recovery and rehabilitation after stroke

    Neuroradiology, Vol. 59, Núm. 4, pp. 343-351

  2. High-permeability region size on perfusion CT predicts hemorrhagic transformation after intravenous thrombolysis in stroke

    PLoS ONE, Vol. 12, Núm. 11

  3. Malignant cutaneous mixed tumor with sebaceous differentiation

    Romanian Journal of Morphology and Embryology, Vol. 58, Núm. 3, pp. 977-982

2016

  1. Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II

    European Heart Journal, Vol. 37, Núm. 33, pp. 2591-2601

  2. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

  4. Specific premature epigenetic aging of cartilage in osteoarthritis

    Aging, Vol. 8, Núm. 9, pp. 2222-2231

2015

  1. Performance of gene-expression profiling test score variability to predict future clinical events in heart transplant recipients

    BMC Cardiovascular Disorders, Vol. 15, Núm. 1

2011

  1. Report from a consensus conference on antibody-mediated rejection in heart transplantation

    Journal of Heart and Lung Transplantation, Vol. 30, Núm. 3, pp. 252-269